https://www.selleckchem.com/products/ds-6051b.html
23-0.58, P 0.001), procedural urgency (HR 0.40; 95% CI 0.23-0.71, P = 0.002) and post-treatment chemoradiotherapy (HR 0.29, 95% CI 0.15-0.56, P 0.001). The beneficial impact observed supports the further use of tracheobronchial stenting in malignant CAO. The use of self-expanding metal stents is encouraged. The beneficial impact observed supports the further use of tracheobronchial stenting in malignant CAO. The use of self-expanding metal stents is encouraged.Among early-stage lung cancers that show ground-glass nodules on c
Like
Comment
Share
